Gene expression analysis using the Parkinson’s disease map reveals early effects of alpha-synuclein on PD pathogenesis
Objective: The identification of early disease markers for Parkinson's disease (PD) is essential, since the disease is already in an advanced state when motor symptoms…Exploring structural covariance networks of gray matter in Parkinson’s disease
Objective: To investigate whether structural covariance networks (SCNs) can be used to detect disease-specific patterns of gray matter atrophy in Parkinson's disease (PD) and secondly,…Reward insensitivity differentiates apathy from depression in Parkinson’s disease
Objective: To determine if a potential cause of apathy in Parkinson's disease (PD) might be insensitivity to rewards, establish if this differentiates apathy from depression…Localization and functional study of synaptic vesicle protein synaptogyrin-3 (SYNGR3) on dopaminergic neuronal system
Objective: To investigate (1) the intracellular localization of SYNGR3 and its interaction with dopamine transporter (DAT); (2) how expression of SYNGR3 in neurons affects dopamine…Visual vs. automated analysis of [123I]FP-CIT SPECT scans in patients with parkinsonism
Objective: To investigate the differences between visual and automated analyses of brain dopamine transporter (DAT) SPECT scans. Background: Clinical evaluation of DAT SPECT scans typically…Improving clinical detection of balance deficits in individuals with Parkinson’s disease with and without freezing of gait and the effects of dopaminergic replacement therapy
Objective: Since it has been argued that PD+FOG have greater sensory impairments compared to PD-FOG, the current study evaluated whether the modified Clinical Test of…Optimization of 6-hydroxydopamine animal model of early stage Parkinson´s disease for the assessment of neurorestorative therapies
Objective: To optimize a simple unilateral partial 6-hydroxydopamine (6-OHDA) lesion protocol that would produce 40-60% striatal dopamine (DA) depletion with detectable motor deficits and to…The role of striatal dopaminergic terminals in early de novo PD patients with speech impairment
Objective: To assess the role of striatal dopaminergic terminals in early de novo (untreated) Parkinson's disease (PD) patients with impairment of speech. Background: Dopamine has…Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism
Objective: To study effect of dopamine and L-3,4 - dihydroxyphenylalanine in treatment of experimental parkinsonism. Background: Prospects of treatment of Parkinson's disease are also closely…Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease
Objective: The objective of our study was to characterize the behavioral phenotype of the transgenic LRRK-2 rat in the context of PD model and to…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.